Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of “Hold” from Brokerages

Omnicell, Inc. (NASDAQ:OMCL) has earned a consensus recommendation of “Hold” from the six ratings firms that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $52.33.

Several brokerages recently commented on OMCL. JPMorgan Chase & Co. upped their price target on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Bank of America reduced their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, December 10th. Wells Fargo & Company reduced their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Finally, Craig Hallum raised their price objective on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $39.72 on Monday. The stock’s fifty day simple moving average is $42.96 and its 200 day simple moving average is $43.86. The stock has a market capitalization of $1.84 billion, a price-to-earnings ratio of 147.12, a PEG ratio of 7.53 and a beta of 0.78. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, sell-side analysts forecast that Omnicell will post 1.09 earnings per share for the current fiscal year.

Insider Activity at Omnicell

In other news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.64% of the company’s stock.

Institutional Investors Weigh In On Omnicell

Several large investors have recently made changes to their positions in the company. Victory Capital Management Inc. grew its position in Omnicell by 11,982.3% in the third quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock worth $50,071,000 after acquiring an additional 1,138,921 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Omnicell during the 3rd quarter worth about $32,721,000. Lazard Asset Management LLC increased its holdings in shares of Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock valued at $73,093,000 after acquiring an additional 737,536 shares during the last quarter. Toronto Dominion Bank acquired a new position in shares of Omnicell during the 4th quarter valued at about $30,637,000. Finally, Dimensional Fund Advisors LP raised its holdings in Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after acquiring an additional 394,820 shares during the period. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.